Daily cost of β-adrenergic blocker therapy

Archives of Ophthalmology

Volumn 115, Issue 7, 1997, Pages 853-856

  Stewart, William C ^a,b   Sine, Cheryl ^a,b,c   Cafe, Elin ^a,b,d   Minno, George E ^a,e,f   Hunt, Hurshdl H ^a,d,g  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CIBA Vision Corporation   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e ALLERGAN INC   (United States)

^f Mercfc Inc   (United States)

^g Otsuha America Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARTEOLOL; LEVOBUNOLOL; METIPRANOLOL; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; INTRAOCULAR HYPOTENSION; PRIORITY JOURNAL;

EID: 0030803039     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1997.01100160023003     Document Type: Article

References (13)

1. Dubiner HB, Hill R, Kaufman H, et al. Timolol hemihydrate vs timolol maleate in ocular hypertension and open-angle glaucoma. Am J Ophthalmol. 1996;121: 522-528.
2. Beehler CC, Stewart WC, MacDonald DK, et al. A comparison of the ocular hype-tensive efficacy of twice-daily 0.25% levobunolol to 0.5% timolol in patients previously treated with 0.5% timolol. J Glaucoma. 1992;1:237-242.
3. Stewart WC, Shields MB, Alien RC, et al. A three-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. GraefesArch Clin Exp Ophthalmol. 1991:229:258-261.
4. Serie JB, Lustgarten JS, Podos SM. A clinical trial of metipranolol, a noncardioselective beta-adrenergic antagonist, in ocular hypertension. Am J OphthalmoJ. 1991;112:302-307.
5. Laurence J, Holder D, Vogel R, et al. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J Glaucoma. 1993:2:177-182.
6. Hartenbaum D, Stek M, Haggert B, et al. Quantitative and cost evaluation of three antiglaucoma beta-blocker agents: Timoptic-XE versus two generic levobunolol products. Am J Managed Care. 1996;2:157-162.
7. Ball SF, Schneider E. Cost of p-adrenergic receptor blocking agents for ocular hypertension. Arch Ophthalmol. 1992;110:654-657.
8. Connors KA. A Textbook of Pharmaceutical Analysis. New York, NY: John Wiley & Sons Inc; 1967:260-267.
9. Stewart WC, Castelli WP. Systemic side effects of topical -adrenergic blockers. ClinCardiol. 1996;19:691-697.
10. Lederer CM Jr, Harold RE. Drop size of commercial glaucoma medications. Am J Ophthalmol. 1986:101:691-694.
11. Sorenson SJ, Abel SR. Drop size of ocular carteolol hydrochloride. Am J Hosp Pharm. 1994;51:1470-1473.
12. Wandel T, Fishman D, Novack GD, Kelley E, Chen KS. Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily. Ophthalmology. 1988:95:252-255.
13. Rakofsky SI, Melamed S, Cohen JS, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice daily levobunolol treatment. Ophthalmology. 1989:96:8-11.